This invention in general relates to medical equipments, specifically a novel kind of metered dose inhaler with a resonating (sound creating) pathway for easy coordination and delivering of drugs to lungs where the drug is absorbed, works and producing relief.
Existing Inhalers used by Asthmatics are metered dose pressure inhalers [called MDI] that send a spray of drug with evaporating propellant and a dry powder inhaler that has no propellant. This device belongs to the pressure inhaler type. Existing MDI inhalers use a multidose vial with drugs suspended in an evaporative medium fitted in a plastic body with a short and wide mouthpiece. The drug mist is released in the short and wide mouthpiece, with a wide divergent mist that coats the mouth and only 5% is sucked into the lungs. The sucking of drug is difficult and wastes the drug, as mouth coating with 5% drug deposit in lungs and 90% failure rate. Dry powder inhalers are also inefficient as drug particles stick together as large poorly absorbed masses with oral deposit that needs water to swallow with 10% deposit in lungs. The metered dose inhalers give 5-micron mist uniformly for easy absorption in lungs and are easy to use than dry powder inhalers. The following description gives critical examination of the inhalers known in the art with its shortcomings. Further in order to over come the problem associated with prior art inhalers, the invention offers the solution to overcome the impediments in the construction and the process of using the inhaler.
Defects in the existing metered dose devices are as follows:
An extensive search has been carried out using the Internet and related patent specifications were studied for alerting, no mouth coating inhalers. Since the present invention is radically different, the inventor is unable to site any patent specification out of the available databases except WO/03/013634 [also invented by us] on which it is improved. WO/03/013634 is an alerting inhaler with whistle, or visual alert for correct coordination and without air filter. Whistle is loud and good for kids but adults need a softer sound alert without revealing sickness to others. The new invention has a resonating soft sound as air is inhaled for correct coordination without a whistle, has an air filter to clean air and needed further experimentation, changes in structure for optimum spray size and velocity and a novel simple but novel dose counter. Proteins (insulin) can be inhaled with modification.
Ideal inhaler must release a drug spray without coating the mouth. Spray width must be as wide as the windpipe diameter [not more] and of low velocity with longer duration of spray for easy inhalation into lungs. The critical air passages width for slow deep inhalation must be less than 8 mm. A sound at start of inhalation will help in correct trigger and spray release for all drug deposit in lungs. Mouth coating should be avoided with back of mouth release. Existing inhalers are not ideal as the mouthpiece is 3.5 sq.cms in area, no alert, large drug spray diameter of 3-4 cms [wind pipes is 2 cm], difficult to train or use! This invention is easy for children and aged who can now suck deep and vigorously and creates sound for easy coordination, leading to good use of the new inhaler.
Further the invention is addressed to the process of using the new inhaler, which is unique in design and construction, working, use and different.
It is another object of this invention is to invent a novel inhaler which has a lower mouth coating mechanism which helps to deposit the drug only in the lungs correctly.
It is another object of this invention is to invent a novel inhaler with a dose counter and which allows slow and deep inspiration of air, which gives more time for spray creation and spread of spray deeply into the lungs for better drug deposit and relief.
Further objects of the invention will be clear from the ensuring description.
The inhaler comprises of a plastic body with a drug vial part and a novel divergent cone shaped long mouthpiece. The drug vial part has a socket for the drug vial and a nozzle for release of spray. The mouthpiece is different from all existing inhalers with a narrow inner end and diverges in a long thin cone such that the drug is deposited in the back of mouth, and propels the drug spray with the inspired air to flow into the lungs.
The air enters the cone shaped mouthpiece in a small hole with a thin baffle across for resonation and has an air filter for trapping dust and germs for safe inhalation. The hole is just small for long, deep, slow inhalation with the air path for easy pressing and release of drug spray. The sound helps in correct start of spray in inhalation. Dose counter is simple.
These and other objects and features of the invention will become more apparent upon perusal of following description taken in conjunction with accompanying drawings wherein:
The following specification describes salient features of invention, the method of construction, the method of use and the advantages of the novel invention.
The novel inhaler has a plastic body with a drug vial part and a mouthpiece. The drug vial with needed drug in the vial is fitted to the vial part. The mouthpiece is a longer divergent cone that releases the drug spray at the back of mouth without mouth coating. The mouthpiece has a small hole for airflow to develop deep, long slow inhalation that deposits the drug into the lungs without mouth waste. The mouthpiece directs the spray into wind passages and lungs for good effect. An in built dose counter reveals dose used.
The novel inhaler according to the invention is loaded with drug vial and kept in mouth, air is sucked in through the mouthpiece, a sound is heard which helps to trigger the spray. Drug is now released as a soft spray at the back of mouthpiece, which travels to lungs for better effect.
The novel inhaler according to invention is better because of slow, deeper inspiration breathing through a smaller air hole of mouth piece, long mouth piece that releases drug spray into wind passages without mouth coating unlike existing inhalers, which spray the mouth, need larger suction effort as the drug is sucked from a wider mouth piece (difficult for kids and aged) and do not facilitate deep inspiration for more drug spread in the lungs with no dose counters.
The novel inhaler according to invention needs a lower suction effort by the user to spray (now easy for kids & aged), directs more spray into wind passages without mouth coating and promotes longer and deeper inspiration for the spray to spread to all areas of the lungs through smaller air hole less than 8 mm (for slow deep inspiration) to blow and spray the drug as the air is sucked. The same volume of air sucked through a smaller area takes longer time. The chest muscles also work deeper for forceful inhalation and spread of drug into lungs.
The conventional existing inhaler
The new inhaler
The device alerts the user to trigger the device in inspiration, does not spray into mouth, directs flow of mist maximally to air passages delivering correct doses, and is safe for children, aged, even in disorientation! A filter (14) made of paper or plastic mesh and fitting on the hole (12) filters air dust and germs for safe inhalation even in polluted air! A dose counter comprises the counter (15) with three rolling digits fitted to inhaler body. A plate (16) fitted to top of the drug vial with a handle (17) engages the counter on inhaler body and when pressed and moves the counter, showing dose available or used.
To use, the novel device's mouthpiece is kept between the lips. The air hole of mouthpiece allows air to be sucked in inspiration! The suction of air creates a small sound, which alerts the user to press the drug vial! The sound is a novel indicator of suction of air in inspiration! The drug vial has the drug(s) in solvent with propellant to spray. The mouthpiece is longer and projects into the mouth longer as in
The inhaler is made of plastic with the orifices, nozzle incorporated as a unit or as separate segments easily assembled.
In
The device can be modified. The mouthpiece tube is made as two pieces adjusted on a screw or sliding mechanism. Electronic sensing, spraying and counting are possible but will make the device costly and heavy. Baffle may produce sound of any type. A rotating wheel in a transparent air inlet will also serve as alert to people who do not want sound alert but need visual clue. The body may be a transparent plastic with a handle for easy pressing of the drug vial. Various shapes for body [e.g. oval] and divergent mouthpiece [hexagonal] may be used. A handle for holding and easy pressing can be used. Air hole may be on the mouthpiece outside body. Dose available or used-is indicated.
Drug vial means a unit comprising a can, a crimped cap covering the mouth of the can, and a drug-metering valve situated in the cap, also includes a suitable channeling device, which delivers a predetermined amount of drug formulation upon each activation. The channeling device may comprise, for example, an actuating device for the valve and a cylindrical or cone-like passage through which medicament may be delivered from the filled can via the valve to the mouth of a patient, e.g. a mouthpiece actuator.
The term “drug formulation” means active drug (or a physiologically acceptable solvate thereof) optionally in combination with one or more other pharmacologically active agents such as other anti-inflammatory agents, analgesic agents or other respiratory drugs and optionally containing one or more excipients, and a propellant. The term “excipients” as used herein means chemical agents having little or no pharmacological activity (for the quantities used) but which enhance the drug formulation or the performance of the system. For example, excipients include but are not limited to surfactants, preservatives, flavorings, antioxidants, antiaggregating agents, and cosolvents, e.g., ethanol and diethyl ether.
A polar cosolvent such as C.sub.2-6 aliphatic alcohols and polyols e.g. ethanol, isopropanol and propylene glycol, preferably ethanol, may be included in the drug formulation in the desired amount, either as the only excipient or in addition to other excipients such as surfactants. Suitably, the drug formulation may contain 0.01 to 5% w/w based on the propellant of a polar cosolvent e.g. ethanol, preferably 0.1 to 5% w/w e.g. about 0.1 to 1% w/w.
Drug formulation for use in the invention may, if desired, contain one or more other pharmacologically active agents, selected from any suitable drug useful in inhalation therapy. Medicaments may be selected from, for example, sildenafil for pulmonary hypertension, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; antiinfectives e.g. cephalosporins, pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. beclomethasone, fluticasone propionate, flunisolide, budesonide, tipredane or triamcinolone acetonide; antitussives, e.g. noscapine; bronchodilators, e.g. salbutamol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, albuterol, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline,or(−)-4-amino-3,5-dichloro-.alpha.[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol; diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, e.g. insulin or glucagon and genetic fragments or anti cancer drugs or any such lung absorbable drugs. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimize the solubility of the medicament in the propellant.
Drug formulations for Asthma may contain fluticasone propionate (or a physiologically acceptable solvate) in combination with a bronchodilator such as salbutamol (e.g. as the free base or the sulphate salt) or salmeterol (e.g. as the xinafoate salt). Combinations for the other diseases as sildenafil for pulmonary hypertension, insulin for diabetes, luprolide for prostrate cancer etc may be used for treatment.
“Propellants” mean pharmacologically inert liquids with boiling points from about room temperature (25.degree. C.) to about −25.degree. C. which singly or in combination exert a high vapor pressure at room temperature. Upon activation of the drug vial, the high vapor pressure of the propellant in the MDI forces a metered amount of drug formulation out through the metering valve. Then the propellant very rapidly vaporizes dispersing the drug particles. The propellants used in the present invention are low boiling fluorocarbons, HFA, etc.
Drug combinations for use in the invention may be free or substantially free of formulation excipients e.g. surfactants and cosolvents etc. and are advantageous since they may be substantially taste and odour free, less irritant and less toxic than excipient-containing formulations. Thus, a preferred drug formulation consists of fluticasone propionate, or it's physiologically acceptable salt, optionally in combination with one or more other pharmacologically active agents particularly salmeterol (e.g. in the form of the xinafoate salt), and a propellant.
Drug formulations for use in the invention may be free or substantially free of surfactant. Most often the drug vial can and cap are made of aluminum or an alloy of aluminum, although other metals not affected by the drug formulation, such as stainless steel, an alloy of copper or tin plate, glass or plastic may be used.
The drug metering valve consists of parts usually made of stainless steel, a pharmacologically inert and propellant resistant polymer, such as acetal, polyamide (e.g., Nylon.RTM.), polycarbonate, polyester, fluorocarbon polymer (e.g., Teflon.RTM.) or a combination of these materials. Additionally, seals and “O” rings of various materials (e.g., nitrile rubbers, polyurethane, acetyl resin, fluorocarbon polymers), or other elastomeric materials are employed in and around the valve. Particularly preferred coatings for inside of drug vial are pure PFA, FEP and blends of PTFE and polyethersulphone (PES).
The particle size of the particular (e.g., micronised) drug should be less than 20 microns, and, in particular, in the range of 1-10 microns, e.g., 1-5 microns.
It will be apparent to those skilled in the art that modifications to the invention described herein can readily be made without departing from the spirit of the invention. Protection is sought for all the subject matter described herein including any such modifications.
Number | Date | Country | Kind |
---|---|---|---|
PCT/IN04/00372 | Dec 2004 | IN | national |
WO 2006 059340 | Dec 2004 | WO | international |